Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19386710 | 0.87 | NOS1 (0.45) | NOS1SLC6A3TRPM5RAB9ASMN1; SMN2 | |
| SCHEMBL24027177 | 0.84 | NOS1 (0.38) | NOS1SLC6A3TRPM5RAB9A | |
| SCHEMBL6703014 | 0.82 | NOS1 (0.41) | NOS1SLC6A3TRPM5RAB9A | |
| SCHEMBL24297619 | 0.82 | NOS1 (0.36) | NOS1SLC6A3TRPM5RAB9AALDH1A1 | |
| SCHEMBL13142433 | 0.78 | NOS1 (0.48) | NOS1SLC6A3TRPM5RAB9ASMN1; SMN2 | |
| SCHEMBL21325317 | 0.77 | RAB9A (0.32) | RAB9ANPC1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL14298745 | 0.77 | NOS1 (0.35) | NOS1SLC6A3TRPM5RAB9A | |
| SCHEMBL127877 | 0.76 | — | — | |
| SCHEMBL9917320 | 0.76 | TRPM5 (0.39) | TRPM5 | |
| SCHEMBL11922139 | 0.76 | LOXL2 (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218004-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-07-04 | — | — | US | disclosed |
| EP-4329463-A2 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Universal Display Corporation (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4001287-B1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORP (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230337520-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230337520-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230212207-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212139-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230151039-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151039-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230146148-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230128198-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230124696-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230045960-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-16 | — | — | US | disclosed |
| US-11530210-B2 | Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-20 | — | — | US | disclosed |
| US-20220165967-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2022-05-26 | — | — | US | disclosed |
| EP-4001287-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Universal Display Corporation (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20220077409-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2022-03-10 | — | — | US | disclosed |
| US-20210017169-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-21 | — | — | US | disclosed |
| US-10781216-B2 | Pyrrolo [3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2020-09-22 | — | — | US | disclosed |
| US-20160168150-A1 | PYRROLO[3,2-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045960-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | NOS1 3932/4885SLC6A3 1876/4885TRPM5 1038/4885 |
| US-20230146148-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, ICOSLG | NOS1 925/4885SLC6A3 3118/4885TRPM5 88/4885 |
| US-20210017169-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | NOS1 3932/4885SLC6A3 1876/4885TRPM5 1038/4885 |
| US-20230212207-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OTC, OCIAD1 | NOS1 1282/4885SLC6A3 2895/4885TRPM5 285/4885 |
| US-20160168150-A1 | PYRROLO[3,2-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES | TYMS, TYMP, DPYD | NOS1 4365/4885SLC6A3 3585/4885TRPM5 4334/4885 |
| US-20230124696-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, CCND1 | NOS1 852/4885SLC6A3 3628/4885TRPM5 1100/4885 |
| US-20230337520-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LBR, LPO, LPL | NOS1 2487/4885SLC6A3 3586/4885TRPM5 561/4885 |
| US-20230128198-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | AURKA, AURKC, AURKB | NOS1 4219/4885SLC6A3 4590/4885TRPM5 3796/4885 |
| US-11530210-B2 | Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | NOS1 3932/4885SLC6A3 1876/4885TRPM5 1038/4885 |
| US-20230212139-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | NOS1 581/4885SLC6A3 899/4885TRPM5 142/4885 |
| US-20220165967-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, ICOSLG | NOS1 1713/4885SLC6A3 3758/4885TRPM5 80/4885 |
| US-20220077409-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, ODC1, OTC | NOS1 1503/4885SLC6A3 2859/4885TRPM5 246/4885 |
| US-10781216-B2 | Pyrrolo [3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | TYMS, TYMP, DPYD | NOS1 4365/4885SLC6A3 3585/4885TRPM5 4334/4885 |
| US-20230151039-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | RPS4X, SOD1, CNKSR1 | NOS1 1853/4885SLC6A3 4250/4885TRPM5 1109/4885 |
| US-20240218004-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, CCND2 | NOS1 1044/4885SLC6A3 4573/4885TRPM5 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.